143 related articles for article (PubMed ID: 16416330)
21. 99mTc-MDP accumulation mechanisms in bone.
Kanishi D
Oral Surg Oral Med Oral Pathol; 1993 Feb; 75(2):239-46. PubMed ID: 8381217
[TBL] [Abstract][Full Text] [Related]
22. Does cisplatin chemotherapy decrease the MDP uptake of normal bone? An experimental study.
Ozdogan O; Ertay T; Arslan G; Sisman AR; Capa Kaya G; Yilmaz O; Coker C; Gure A; Durak H
Ann Nucl Med; 2008 Jun; 22(5):357-62. PubMed ID: 18600412
[TBL] [Abstract][Full Text] [Related]
23. Is (99m)Tc-labelled pamidronate a better agent than (99m)Tc-medronate for bone imaging?
Kumar V; Kumar D; Howman-Giles RB; Little DG
Nucl Med Commun; 2007 Feb; 28(2):101-7. PubMed ID: 17198350
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of samarium-153 and holmium-166-EDTMP in the normal baboon model.
Louw WK; Dormehl IC; van Rensburg AJ; Hugo N; Alberts AS; Forsyth OE; Beverley G; Sweetlove MA; Marais J; Lötter MG; van Aswegen A
Nucl Med Biol; 1996 Nov; 23(8):935-40. PubMed ID: 9004281
[TBL] [Abstract][Full Text] [Related]
25. Prospective Comparison of 99mTc-MDP Scintigraphy, Combined 18F-NaF and 18F-FDG PET/CT, and Whole-Body MRI in Patients with Breast and Prostate Cancer.
Minamimoto R; Loening A; Jamali M; Barkhodari A; Mosci C; Jackson T; Obara P; Taviani V; Gambhir SS; Vasanawala S; Iagaru A
J Nucl Med; 2015 Dec; 56(12):1862-8. PubMed ID: 26405167
[TBL] [Abstract][Full Text] [Related]
26. Estimated human absorbed dose of ¹⁷⁷Lu-BPAMD based on mice data: Comparison with ¹⁷⁷Lu-EDTMP.
Yousefnia H; Zolghadri S; Shanehsazzadeh S
Appl Radiat Isot; 2015 Oct; 104():128-35. PubMed ID: 26163291
[TBL] [Abstract][Full Text] [Related]
27. Impact of ¹⁸F-fluoride PET-CT on implementing early treatment of painful bone metastases with Sm-153 EDTMP.
Storto G; Gallicchio R; Pellegrino T; Nardelli A; De Luca S; Capacchione D; Sirignano C; Pace L
Nucl Med Biol; 2013 May; 40(4):518-23. PubMed ID: 23522973
[TBL] [Abstract][Full Text] [Related]
28. Mechanism of accumulation of 99mTc-MDP to bone: correlation of in vivo data with in vitro data.
Okamoto YM
Radiat Med; 1997; 15(4):209-15. PubMed ID: 9311035
[TBL] [Abstract][Full Text] [Related]
29. A study to determine the dependence of 99mTc-MDP protein binding on plasma clearance and serum albumin concentration.
Moore AE; Blake GM; Fogelman I
Nucl Med Commun; 2007 Mar; 28(3):187-92. PubMed ID: 17264777
[TBL] [Abstract][Full Text] [Related]
30. [The measurement of 153Sm-EDTMP bone uptake rate and its relationship with therapeutic effect].
Li L; Liang Z; Deng H; Li Y; Zhang X; Yang X
Hua Xi Yi Ke Da Xue Xue Bao; 2001 Sep; 32(3):446-8. PubMed ID: 12536590
[TBL] [Abstract][Full Text] [Related]
31. Uptake and biodistribution of technetium-99m-MD32P during rat tibial bone repair.
Schwartz Z; Shani J; Soskolne WA; Touma H; Amir D; Sela J
J Nucl Med; 1993 Jan; 34(1):104-8. PubMed ID: 8418249
[TBL] [Abstract][Full Text] [Related]
32. Comparison of the diagnostic and prognostic values of 99mTc-MDP-planar bone scintigraphy, 131I-SPECT/CT and 18F-FDG-PET/CT for the detection of bone metastases from differentiated thyroid cancer.
Qiu ZL; Xue YL; Song HJ; Luo QY
Nucl Med Commun; 2012 Dec; 33(12):1232-42. PubMed ID: 23111353
[TBL] [Abstract][Full Text] [Related]
33. Age- and sex-related bone uptake of Tc-99m-HDP measured by whole-body bone scanning.
Brenner W; Sieweke N; Bohuslavizki KH; Kampen WU; Zuhayra M; Clausen M; Henze E
Nuklearmedizin; 2000 Aug; 39(5):127-32. PubMed ID: 10984888
[TBL] [Abstract][Full Text] [Related]
34. Samarium-153-EDTMP biodistribution and dosimetry estimation.
Eary JF; Collins C; Stabin M; Vernon C; Petersdorf S; Baker M; Hartnett S; Ferency S; Addison SJ; Appelbaum F
J Nucl Med; 1993 Jul; 34(7):1031-6. PubMed ID: 7686217
[TBL] [Abstract][Full Text] [Related]
35. A prospective study of risedronate on regional bone metabolism and blood flow at the lumbar spine measured by 18F-fluoride positron emission tomography.
Frost ML; Cook GJ; Blake GM; Marsden PK; Benatar NA; Fogelman I
J Bone Miner Res; 2003 Dec; 18(12):2215-22. PubMed ID: 14672357
[TBL] [Abstract][Full Text] [Related]
36. Pathophysiological premises to radiotracers for bone metastases.
Cuccurullo V; Cascini G; Rossi A; Tamburrini O; Rotondo A; Mansi L
Q J Nucl Med Mol Imaging; 2011 Aug; 55(4):353-73. PubMed ID: 21738112
[TBL] [Abstract][Full Text] [Related]
37. What is the source of the skeletal affinity of 99mTc-V-DMSA?
Athanasoulis T; Koutsikos J; Zerva C
Eur J Nucl Med Mol Imaging; 2004 Dec; 31(12):1673-4; author reply 1675-6. PubMed ID: 15452672
[No Abstract] [Full Text] [Related]
38. Production of 105Rh-EDTMP and its bone accumulation.
Ando A; Ando I; Tonami N; Kinuya S; Okamoto N; Sugimoto M; Fukuda N; Matsumoto S
Appl Radiat Isot; 2000 Feb; 52(2):211-5. PubMed ID: 10697730
[TBL] [Abstract][Full Text] [Related]
39. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT.
Even-Sapir E; Metser U; Mishani E; Lievshitz G; Lerman H; Leibovitch I
J Nucl Med; 2006 Feb; 47(2):287-97. PubMed ID: 16455635
[TBL] [Abstract][Full Text] [Related]
40. Radiopharmacokinetic data for 99mTc-ABP--a new radiopharmaceutical for bone scanning: comparison with 99mTc-MDP.
Arteaga de Murphy C; Meléndez-Alafort L; Montoya-Molina CE; Sepúlveda-Méndez J
Nucl Med Biol; 1997 Jan; 24(1):27-33. PubMed ID: 9080472
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
